DUBLIN--(BUSINESS WIRE)--The "Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.
Global Eczema Therapeutics Market: About this market
The eczema therapeutics market analysis considers sales from atopic dermatitis, contact dermatitis, and other indication. Our study also finds the sales of eczema therapeutics in Asia, Europe, North America, and ROW. In 2019, the atopic dermatitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of chronic, highly pruritic inflammatory skin disorders will play a significant role in the atopic dermatitis segment to maintain its market position. Also, our global eczema therapeutics market report looks at factors such as the high prevalence of atopic dermatitis, strong pipeline landscapes, and major product launches. However, side effects associated with corticosteroids, intense competition among vendors, and stringent regulatory guidelines may hamper the growth of the eczema therapeutics industry over the forecast period.
Global Eczema Therapeutics Market: Overview
High prevalence of atopic dermatitis
Exposure to skin irritants including soaps or cleaners and allergens such as pet dander, pollen, or peanuts can lead to eczema. It is also caused by infections, dry skin, and stress. Atopic dermatitis is one of the most prevalent forms of eczema which requires multiple visits to dermatologists and numerous medications for treatment. China, India, and Japan are the three major revenue contributors to the market as these regions of Asia constitute a huge patient pool and consequently exhibit a high demand for eczema therapeutics. Thus, the high prevalence of atopic dermatitis will lead to the expansion of the global eczema therapeutics market at a CAGR of over 9% during the forecast period.
Increasing healthcare expenditure
Healthcare expenditure is increasing owing to the growing prevalence of allergic and inflammatory skin diseases in people globally. For the treatment of highly prevalent diseases such as atopic dermatitis, dermatologists are prescribing many OTC drugs and generic medications such as corticosteroids, antihistamines, and topical antiseptics due to the high number of clinical visits. The market is also witnessing an increased adoption of expensive, novel, and branded drugs for a more effective treatment. Moreover, the growing awareness of the need for early diagnosis of skin diseases, as well as the risks of negligence in seeking timely medical help, is making people increasingly health-conscious, which, in turn, is organically increasing the healthcare expenditure.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Value chain analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2019
- Market size and forecast 2019-2024
- Market outlook
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity
PART 08: MARKET SEGMENTATION BY INDICATION
- Market segmentation by indication
- Comparison by indication
- Atopic dermatitis - Market size and forecast 2019-2024
- Contact dermatitis - Market size and forecast 2019-2024
- Other indication - Market size and forecast 2019-2024
- Market opportunity by indication
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Business strategies
- Geopolitical uncertainties
- Increasing healthcare expenditure
PART 12: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie Inc.
- Alliance Pharma Plc
- Bausch Health Companies Inc.
- Bayer AG
- Eli Lilly and Co.
- Encore Dermatology Inc.
- LEO Pharma AS
- Mylan NV
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/i38yts